Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summary
Year: 2025
Type: article
Abstract: Plain Language SummaryWhat is this summary about?This summary describes the results of a study that used patient data from a large database containing medical records of millions of people treated in cancer clinics across the United States. This study looked at specific treatments for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer that had spread to their lungs or liver. This study compared two different treatments for these patients:1) palbociclib plus an aromatase inhibitor2) an aromatase inhibitor aloneThe researchers wanted to find out whether adding palbociclib to an aromatase inhibitor helped patients with HR+/HER2- metastatic breast cancer that had spread to their lungs or liver live longer than treatment with an aromatase inhibitor alone.What were the results?People whose cancer had spread to their lungs or liver who took palbociclib plus an aromatase inhibitor lived longer overall, and lived longer without their cancer getting worse, than those who took an aromatase inhibitor alone.What do the results mean?These results support the use of palbociclib plus an aromatase inhibitor as a first treatment for people with HR+/HER2- breast cancer that had spread to the lungs or liver.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Source: Future Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4408991036